Maravai LifeSciences Holdings, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. May 5, 2025 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit due to allegations of false and misleading statements regarding its financial reporting and revenue recognition practices during the specified class period [3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Maravai securities between August 7, 2024, and February 24, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Maravai - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting, particularly concerning revenue recognition [3]. - It is alleged that Maravai improperly recognized approximately $3.9 million in revenue during fiscal year 2024 due to an error in recording revenue [4]. - The company is also accused of overstating its goodwill related to its acquisition of Alphazyme LLC [3][4]. Group 3: Impact on Stock Price - Following the announcement of the postponement of its fiscal 2024 earnings release and the need for additional time to complete its financial close, Maravai's stock price fell by nearly 22% [4].